Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration.

Saragovi HU, Galan A, Levin LA.

Front Cell Neurosci. 2019 Jun 6;13:231. doi: 10.3389/fncel.2019.00231. eCollection 2019. Review.

2.

Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation.

Josephy-Hernandez S, Pirvulescu I, Maira M, Aboulkassim T, Wong TP, McKinney RA, Saragovi HU.

PLoS One. 2019 Jun 24;14(6):e0218036. doi: 10.1371/journal.pone.0218036. eCollection 2019.

3.

Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy.

Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU.

Cell Chem Biol. 2019 Jul 18;26(7):1013-1026.e4. doi: 10.1016/j.chembiol.2019.03.018. Epub 2019 May 16.

PMID:
31105061
4.

The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy.

Barcelona PF, Galan A, Nedev H, Jian Y, Sarunic MV, Saragovi HU.

PLoS One. 2018 Jun 21;13(6):e0199079. doi: 10.1371/journal.pone.0199079. eCollection 2018.

5.

UNG-1 and APN-1 are the major enzymes to efficiently repair 5-hydroxymethyluracil DNA lesions in C. elegans.

Papaluca A, Wagner JR, Saragovi HU, Ramotar D.

Sci Rep. 2018 May 1;8(1):6860. doi: 10.1038/s41598-018-25124-1.

6.

Inhibition of CD45 Phosphatase Activity Induces Cell Cycle Arrest and Apoptosis of CD45+ Lymphoid Tumors Ex Vivo and In Vivo.

Perron M, Saragovi HU.

Mol Pharmacol. 2018 Jun;93(6):575-580. doi: 10.1124/mol.117.110908. Epub 2018 Mar 19.

PMID:
29555821
7.

In retinitis pigmentosa TrkC.T1-dependent vectorial Erk activity upregulates glial TNF-α, causing selective neuronal death.

Galán A, Jmaeff S, Barcelona PF, Brahimi F, Sarunic MV, Saragovi HU.

Cell Death Dis. 2017 Dec 14;8(12):3222. doi: 10.1038/s41419-017-0074-8.

8.

p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa.

Platón-Corchado M, Barcelona PF, Jmaeff S, Marchena M, Hernández-Pinto AM, Hernández-Sánchez C, Saragovi HU, de la Rosa EJ.

Cell Death Dis. 2017 Jul 13;8(7):e2922. doi: 10.1038/cddis.2017.306.

9.

Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.

Galan A, Barcelona PF, Nedev H, Sarunic MV, Jian Y, Saragovi HU.

Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2852-2862. doi: 10.1167/iovs.16-20988.

PMID:
28570737
10.

Identification of function-regulating antibodies targeting the receptor protein tyrosine phosphatase sigma ectodomain.

Wu CL, Hardy S, Aubry I, Landry M, Haggarty A, Saragovi HU, Tremblay ML.

PLoS One. 2017 May 30;12(5):e0178489. doi: 10.1371/journal.pone.0178489. eCollection 2017.

11.

The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.

Brahimi F, Maira M, Barcelona PF, Galan A, Aboulkassim T, Teske K, Rogers ML, Bertram L, Wang J, Yousefi M, Rush R, Fabian M, Cashman N, Saragovi HU.

PLoS One. 2016 Oct 3;11(10):e0162307. doi: 10.1371/journal.pone.0162307. eCollection 2016.

12.

p75NTR and Its Ligand ProNGF Activate Paracrine Mechanisms Etiological to the Vascular, Inflammatory, and Neurodegenerative Pathologies of Diabetic Retinopathy.

Barcelona PF, Sitaras N, Galan A, Esquiva G, Jmaeff S, Jian Y, Sarunic MV, Cuenca N, Sapieha P, Saragovi HU.

J Neurosci. 2016 Aug 24;36(34):8826-41. doi: 10.1523/JNEUROSCI.4278-15.2016.

13.

Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm.

Josephy-Hernandez S, Jmaeff S, Pirvulescu I, Aboulkassim T, Saragovi HU.

Neurobiol Dis. 2017 Jan;97(Pt B):139-155. doi: 10.1016/j.nbd.2016.08.004. Epub 2016 Aug 18. Review.

PMID:
27546056
14.

Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology.

Tong W, Maira M, Gagnon M, Saragovi HU.

PLoS One. 2015 Aug 7;10(8):e0134255. doi: 10.1371/journal.pone.0134255. eCollection 2015.

15.
16.

Erratum to: Modulation of p75(NTR) prevents diabetes- and proNGF-induced retinal inflammation and blood-retina barrier breakdown in mice and rats.

Mysona BA, Al-Gayyar MM, Matragoon S, Abdelsaid MA, El-Azab MF, Saragovi HU, El-Remessy AB.

Diabetologia. 2015 Mar;58(3):644. doi: 10.1007/s00125-014-3476-5. No abstract available.

PMID:
25527000
17.

Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells.

Goupil E, Fillion D, Clément S, Luo X, Devost D, Sleno R, Pétrin D, Saragovi HU, Thorin É, Laporte SA, Hébert TE.

J Biol Chem. 2015 Jan 30;290(5):3137-48. doi: 10.1074/jbc.M114.631119. Epub 2014 Dec 15.

18.

Neuronal injury external to the retina rapidly activates retinal glia, followed by elevation of markers for cell cycle re-entry and death in retinal ganglion cells.

Galan A, Dergham P, Escoll P, de-la-Hera A, D'Onofrio PM, Magharious MM, Koeberle PD, Frade JM, Saragovi HU.

PLoS One. 2014 Jul 1;9(7):e101349. doi: 10.1371/journal.pone.0101349. eCollection 2014.

19.

Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors.

Brahimi F, Ko E, Malakhov A, Burgess K, Saragovi HU.

PLoS One. 2014 Mar 6;9(3):e89617. doi: 10.1371/journal.pone.0089617. eCollection 2014.

20.

Allosteric noncompetitive small molecule selective inhibitors of CD45 tyrosine phosphatase suppress T-cell receptor signals and inflammation in vivo.

Perron MD, Chowdhury S, Aubry I, Purisima E, Tremblay ML, Saragovi HU.

Mol Pharmacol. 2014 Apr;85(4):553-63. doi: 10.1124/mol.113.089847. Epub 2014 Jan 28.

PMID:
24473749
21.

Modulation of p75(NTR) prevents diabetes- and proNGF-induced retinal inflammation and blood-retina barrier breakdown in mice and rats.

Mysona BA, Al-Gayyar MM, Matragoon S, Abdelsaid MA, El-Azab MF, Saragovi HU, El-Remessy AB.

Diabetologia. 2013 Oct;56(10):2329-39. doi: 10.1007/s00125-013-2998-6. Epub 2013 Aug 7. Erratum in: Diabetologia. 2014 Jun;57(6):1268. Diabetologia. 2015 Mar;58(3):644.

22.

Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model.

Ettinger K, Lecht S, Arien-Zakay H, Cohen G, Aga-Mizrachi S, Yanay N, Saragovi HU, Nedev H, Marcinkiewicz C, Nevo Y, Lazarovici P.

Cell Signal. 2012 Dec;24(12):2378-88. doi: 10.1016/j.cellsig.2012.08.008. Epub 2012 Aug 30.

PMID:
22960610
23.

Rational design of peptide ligands against a glycolipid by NMR studies.

Tong W, Sprules T, Gehring K, Saragovi HU.

Methods Mol Biol. 2012;928:39-52. doi: 10.1007/978-1-62703-008-3_4.

PMID:
22956132
24.

Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.

Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU.

Oncogene. 2013 May 16;32(20):2527-33. doi: 10.1038/onc.2012.283. Epub 2012 Jul 16.

PMID:
22797066
25.

An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye.

Jain P, Li R, Lama T, Saragovi HU, Cumberlidge G, Meerovitch K.

Exp Eye Res. 2011 Oct;93(4):503-12. doi: 10.1016/j.exer.2011.06.014. Epub 2011 Jun 25.

PMID:
21726552
26.

During glaucoma, alpha2-macroglobulin accumulates in aqueous humor and binds to nerve growth factor, neutralizing neuroprotection.

Bai Y, Sivori D, Woo SB, Neet KE, Lerner SF, Saragovi HU.

Invest Ophthalmol Vis Sci. 2011 Jul 15;52(8):5260-5. doi: 10.1167/iovs.10-6691.

PMID:
21642630
27.

Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory.

Aboulkassim T, Tong XK, Tse YC, Wong TP, Woo SB, Neet KE, Brahimi F, Hamel E, Saragovi HU.

Mol Pharmacol. 2011 Sep;80(3):498-508. doi: 10.1124/mol.111.071332. Epub 2011 May 26.

PMID:
21616921
28.

Longitudinal study of retinal degeneration in a rat using spectral domain optical coherence tomography.

Sarunic MV, Yazdanpanah A, Gibson E, Xu J, Bai Y, Lee S, Saragovi HU, Beg MF.

Opt Express. 2010 Oct 25;18(22):23435-41. doi: 10.1364/OE.18.023435.

PMID:
21164686
29.

Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism.

Bai Y, Dergham P, Nedev H, Xu J, Galan A, Rivera JC, ZhiHua S, Mehta HM, Woo SB, Sarunic MV, Neet KE, Saragovi HU.

J Biol Chem. 2010 Dec 10;285(50):39392-400. doi: 10.1074/jbc.M110.147801. Epub 2010 Oct 13.

30.

A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist.

Brahimi F, Liu J, Malakhov A, Chowdhury S, Purisima EO, Ivanisevic L, Caron A, Burgess K, Saragovi HU.

Biochim Biophys Acta. 2010 Sep;1800(9):1018-26. doi: 10.1016/j.bbagen.2010.06.007. Epub 2010 Jun 19.

31.

In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death.

Bai Y, Shi Z, Zhuo Y, Liu J, Malakhov A, Ko E, Burgess K, Schaefer H, Esteban PF, Tessarollo L, Saragovi HU.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6639-51. doi: 10.1167/iovs.10-5431. Epub 2010 Jun 23.

32.

A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway.

Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Pétrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hébert TE, Laporte SA.

J Biol Chem. 2010 Aug 13;285(33):25624-36. doi: 10.1074/jbc.M110.115196. Epub 2010 Jun 15.

33.

Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists.

Liu J, Brahimi F, Saragovi HU, Burgess K.

J Med Chem. 2010 Jul 8;53(13):5044-8. doi: 10.1021/jm100148d.

34.

An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma.

Bai Y, Xu J, Brahimi F, Zhuo Y, Sarunic MV, Saragovi HU.

Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4722-31. doi: 10.1167/iovs.09-5032. Epub 2010 Mar 31.

PMID:
20357199
35.

Small-molecule ligands of GD2 ganglioside, designed from NMR studies, exhibit induced-fit binding and bioactivity.

Tong W, Gagnon M, Sprules T, Gilbert M, Chowdhury S, Meerovitch K, Hansford K, Purisima EO, Blankenship JW, Cheung NK, Gehring K, Lubell WD, Saragovi HU.

Chem Biol. 2010 Feb 26;17(2):183-94. doi: 10.1016/j.chembiol.2010.01.012.

36.

An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors.

Guillemard V, Ivanisevic L, Garcia AG, Scholten V, Lazo OM, Bronfman FC, Saragovi HU.

Dev Neurobiol. 2010 Feb 15;70(3):150-64. doi: 10.1002/dneu.20776.

37.

A neurotrophic rationale for the therapy of neurodegenerative disorders.

Saragovi HU, Hamel E, Di Polo A.

Curr Alzheimer Res. 2009 Oct;6(5):419-23. Review.

PMID:
19874265
38.

Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Chen D, Brahimi F, Angell Y, Li YC, Moscowicz J, Saragovi HU, Burgess K.

ACS Chem Biol. 2009 Sep 18;4(9):769-81. doi: 10.1021/cb9001415.

39.

Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo.

Bassili M, Birman E, Schor NF, Saragovi HU.

Cancer Chemother Pharmacol. 2010 May;65(6):1047-56. doi: 10.1007/s00280-009-1110-x. Epub 2009 Aug 22.

40.

A peptidomimetic of NT-3 acts as a TrkC antagonist.

Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU.

Peptides. 2009 Oct;30(10):1833-9. doi: 10.1016/j.peptides.2009.07.015. Epub 2009 Jul 30.

41.

VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.

Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F Jr, Hardy P, Joyal JS, Nedev H, Duhamel F, Beauregard K, Heveker N, Saragovi HU, Guillon G, Bouvier M, Lubell WD, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R1009-18. doi: 10.1152/ajpregu.90766.2008. Epub 2009 Jul 29.

42.

Synthesis of biotinyl-TN14003, anti-HIV peptide amide.

Nedev H, Saragovi HU.

Adv Exp Med Biol. 2009;611:155-6. No abstract available.

PMID:
19400137
43.

Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells.

Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A.

Mol Cell Neurosci. 2009 Apr;40(4):410-20. doi: 10.1016/j.mcn.2008.12.005. Epub 2008 Dec 25.

PMID:
19146958
44.

Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.

Kojic LD, Wiseman SM, Ghaidi F, Joshi B, Nedev H, Saragovi HU, Nabi IR.

PLoS One. 2008;3(10):e3597. doi: 10.1371/journal.pone.0003597. Epub 2008 Oct 31.

45.
46.

Alpha2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma.

Shi Z, Rudzinski M, Meerovitch K, Lebrun-Julien F, Birman E, Di Polo A, Saragovi HU.

J Biol Chem. 2008 Oct 24;283(43):29156-65. doi: 10.1074/jbc.M802365200. Epub 2008 Aug 13.

47.

Measurement of lymphokine receptors.

Lowenthal JW, Malek TR, Saragovi H.

Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.1. doi: 10.1002/0471142735.im0601s35.

PMID:
18432801
48.

Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.

Moffett S, Mélançon D, DeCrescenzo G, St-Pierre C, Deschénes F, Saragovi HU, Gold P, Cuello AC.

Hybridoma (Larchmt). 2007 Dec;26(6):363-72.

PMID:
18158780
49.

A combinatorial method for solution-phase synthesis of labeled bivalent beta-turn mimics.

Angell Y, Chen D, Brahimi F, Saragovi HU, Burgess K.

J Am Chem Soc. 2008 Jan 16;130(2):556-65. Epub 2007 Dec 19.

PMID:
18088119
50.

Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo.

Shi Z, Birman E, Saragovi HU.

Dev Neurobiol. 2007 Jun;67(7):884-94. Erratum in: Dev Neurobiol. 2007 Sep 15;67(11):1547-8.

Supplemental Content

Loading ...
Support Center